Physician profile
Alysa D Young
NPI 1447644125
$633.27
in general payments reported to CMS, 2019-2025
14 companies · $205 in 2025
The $205 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $25.45 · 2022: $97.96 · 2023: $63.47 · 2024: $242 · 2025: $205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $510.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $509.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.64 | 2022-2023 | Jardiance |
| Grifols USA, LLC | $106.12 | 2025 | Prolastin-C Liquid |
| Lilly USA, LLC | $92.60 | 2023-2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $58.94 | 2024-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $43.39 | 2023-2024 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $38.57 | 2024-2025 | Farxiga, Airsupra |
| Amgen INC. | $31.45 | 2024 | Otezla, Repatha |
| Inspire Medical Systems, INC. | $27.62 | 2025 | Inspire |
| Medtronic, INC. | $25.45 | 2021 | |
| Ardelyx, INC. | $21.82 | 2024 | Ibsrela |
| Actelion Pharmaceuticals US, INC. | $20.50 | 2024 | Uptravi, Opsumit |
| Sumitomo Pharma America, INC. | $19.37 | 2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $15.35 | 2024 | |
| Idorsia Pharmaceuticals US INC | $13.45 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alysa Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.